Cat. #161904
Caki-2 Cell line
Cat. #: 161904
Availability: 8-10 weeks
Organism: Human
Tissue: Kidney
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Jorgen Fogh, Germain Trempe
Institute: Memorial Sloan-Kettering Cancer Center (MSK)
Primary Citation: Fogh J et al. 1977. Journal of the National Cancer Institute. 59: 221-226. PMID: 327080.
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Caki-2 Cell line
- Cancer: Carcinoma;Genitourinary cancer
- Cancers detailed: Clear cell carcinoma
- Organism: Human
- Gender: Male
- Tissue: Kidney
- Donor: 69-year-old Caucasian male with clear cell carcinoma of the kidney.
- Morphology: Epithelial
- Growth properties: Adherent
- Products or characteristics of interest: Karyotype: hypopentaploid to hypohexaploid (+A2, +A3, +B, +C, +D, +F, +G, -A) with abnormalities including dicentrics, acrocentric fragments, minutes, breaks, and large subtelocentric markers. Isoenzymes: AK-1, 1; ES-D, 1; G6PD, B; GLO-I, 1-2; Me-2, 1; PGM1, 1; PGM3, 1
- Description: Human Renal Cancer Cell Line. Caki-2 is a human clear cell renal cell carcinoma (ccRCC) line that displays epithelial morphology and grows in adherent culture. These cells are a useful preclinical model to study renal cancer. They are relatively less sensitive to 5-fluorouracil and sorafenib (multi-kinase inhibitor of VEGFRs 1-3, PDGFR-b, and Raf-1) compared to Caki-1 cells. The Caki-2 cells have a loss-of-function mutation in the von Hippel-Lindau (VHL) tumour-suppressor protein and are known to form tumours in immunocompromised mice.
- Application: 3D cell culture; Cancer research
- Biosafety level: 1
Target Details
- Target: Antigen expression: Blood Type A; Rh-
Applications
- Application: 3D cell culture; Cancer research
Handling
- Growth medium: McCoy's 5a Medium Modified supplemented with 10% FBS
- Temperature: 37° C
- Shipping conditions: Dry Ice
- Storage medium: Complete growth medium supplemented with 5% (v/v) DMSO
- Str profiling: Amelogenin: X,Y;CSF1PO: 10,12;D13S317: 10;D16S539: 9,13;D5S818: 11;D7S820: 12;TH01: 6;TPOX: 9,11;vWA: 16,17;D3S1358: 14;D21S11: 27,31;D18S51: 17;Penta_E: 7,17;Penta_D: 10,13;D8S1179: 10;FGA: 22;D19S433: 13,14;D2S1338: 17,20
References
- Fogh J et al. 1977. Journal of the National Cancer Institute 59: 221-226. PMID: 327080.
- Miyake M et al. 2012. Oncology Letters. 3: 1195-1202. PMID: 22783417.
